Differential effects of the KRAS gene on recurrence in right- vs left-sided colorectal liver metastases undergoing radiofrequency ablation

Table 3 Univariable and multivariable analyses of prognostic factors for recurrence-free survival for colorectal liver metastases

Prognostic factor	Univariable analysis		Multivariable analysis
	HR (95%CI)	P value	HR (95%CI)	P value
Age (year)	0.890 (0.622-1.273)	0.523
Tumor size > 3 cm	1.070 (0.715-1.602)	0.743
Sex	1.112 (0.776-1.593)	0.563
Right colon	1.072 (0.657-1.748)	0.781
Pathological differentiation/poorly	0.766 (0.430-1.364)	0.366
KRAS mutation	1.507 (1.058-2.148)	0.023	1.526 (1.056-2.207)	0.025
T stage	0.910 (0.461-1.796)	0.786
Lymph node metastasis	1.674 (1.064-2.635)	0.026	1.602 (1.008-2.545)	0.046
Synchronous liver metastasis	0.824 (0.580–1.169)	0.278
No. of liver metastases	1.414 (0.992-2.014)	0.055	1.241 (0.857-1.797)	0.253
Liver metastasis resection pre-RFA	1.414 (0.990-2.019)	0.057	1.418 (0.988-2.034)	0.058
Extrahepatic metastases	1.066 (0.745-1.524)	0.727
CRS	1.238 (0.869-1.762)	0.236
CEA	0.893 (0.563-1.417)	0.631
DFI	1.043 (0.645-1.686)	0.863
Preoperative chemotherapy	1.111 (0.611-2.017)	0.731

DFI: Disease-free interval from primary resection to the diagnosis of liver metastasis; CRS: Clinical risk score, including node-positive primary tumor, DFI < 12 months, more than one liver tumor, size of largest tumor > 3 cm, carcinoembryonic antigen level > 30 ng/mL (mg/L); RFA: Radiofrequency ablation; CEA: Carcinoembryonic antigen.